Seung Ho So

Title: Seung Ho So: Innovator in Angiogenesis Inhibitor Purification

Introduction

Seung Ho So is a notable inventor based in Taejon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the purification of angiogenesis inhibitors. His work has implications for cancer treatment and other medical applications.

Latest Patents

Seung Ho So holds a patent for a process of purifying angiogenesis inhibitors. This invention relates to the purification of angiogenesis inhibitor proteins expressed in recombinant kringle 1-3, also known as greenstatin. The process involves solubilizing, refolding, and purifying the proteins to achieve a pure and active form. The purified greenstatin specifically suppresses endothelial cell proliferation, angiogenesis, and the growth of various cancers, including lung cancer, skin cancer, and brain tumors. This process is applicable for the mass production of angiogenesis inhibitor proteins, which are useful in treating conditions such as glaucoma and retinopathy.

Career Highlights

Seung Ho So is associated with Korea Greencross Corporation, where he continues to advance his research and innovations. His work has positioned him as a key figure in the development of therapeutic agents targeting cancer and other diseases.

Collaborations

He has collaborated with notable colleagues, including Weon Kyoo You and Byung Cheul Ahn, to further enhance the impact of his research in the field.

Conclusion

Seung Ho So's contributions to the purification of angiogenesis inhibitors represent a significant advancement in biotechnology. His innovative processes have the potential to improve treatment options for various medical conditions, particularly in oncology.